Genome wide analysis of BCL3 mediated chemotherapy resistance
Ontology highlight
ABSTRACT: We identify the atypical inhibitor-κB protein, Bcl3, as a novel biomarker in gliomas whose expression level predicts response to therapy. Bcl3 is found at 19q13 and its expression level in glioma is regulated by copy number alteration. Mechanistically, Bcl3 mediates mesenchymal differentiation and its presence promotes resistance to cytotoxic DNA damage.
ORGANISM(S): Homo sapiens
PROVIDER: GSE80729 | GEO | 2018/07/21
REPOSITORIES: GEO
ACCESS DATA